Publications

5543 Results

Minimal residual disease (MRD) status predicts outcomes in patients with follicular lymphoma (FL) treated with chemo-immunotherapy on SWOG S0016 study

Authors
A Danilov;H Li;M Shadman;L Rimsza;A Zebari;S Smith;M LeBlanc;J Friedberg;C Carlson;J Song
Journal / Conference
ASH Annual Meeting (Dec 9-12,2023, San Diego, CA), poster
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S0016

Class III obesity is associated with worse overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203

Authors
MY Zhang;M Othus;K McMillen;H Erba;G Garcia-Manero;J Pagel;M Sorro;M-E Percival
Journal / Conference
ASH Annual Meeting (Dec9-12,2023, San Diego, CA), poster
Year
2023
Research Committee(s)
Leukemia
Study Number(s)
S1203

SWOG S1931 (PROBE): Phase III randomized trial of Immune checkpoint inhibitor (ICI) combination regimen with or without Cytoreductive Nephrectomy (CN) in Advanced Renal Cancer [NCT04510597]

Authors
H Kim;C Tangen;U Vaishampayan;A Tripathi;B Shuch;S Pal;P Barata;A Tan;L Esfeller;P Lara;A Sanchez;SP Lerner;IM Thompson
Journal / Conference
SUO (Society of Urologic Oncology) (Nov 28-Dec 1, Washington, DC), TIPS, poster
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S1931

Progression-Free Survival (PFS) and toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Authors
S Castellino;H Li;A Herrera;A Punnett;M LeBlanc;F Keller;R Drachtman;A Lamble;C Forlenza;A Doan;S Rutherford;A Evens;D Hodgson;S Parsons;R Little;M Smith;J Song;S Smith;JW Friedberg;K Kelly
Journal / Conference
ASH Annual Meeting (Dec 9-12, 2023, San Diego), oral
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged =60 years) enrolled on SWOG S1826

Authors
S Rutherford;H Li;A Herrera;M LeBlanc;S Ahmed;K Davison;C Casulo;N Bartlett;J Tuscano;B Hess;P Torka;P Kumar;R Jacobs;J Song;S Castellino;B Kahl;J Leonard;S Smith;JW Friedberg;A Evens
Journal / Conference
ASH Annual Meeting (Dec9-12,2023, San Diego, CA), oral
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Novel Approach to Accelerate Lung Cancer Research: LungMap and the Potential of Public-Private Partnerships

Authors
RS Herbst;CD Blanke;E Sigal
Journal / Conference
Clinical Cancer Research Oct 30. doi: 10.1158/1078-0432.CCR-23-2690. Online ahead of print
Year
2023
Research Committee(s)
Lung
PMID
PMID37903180
PMC
PMC10767300
Study Number(s)
LUNGMAP

Ibrutinib Added to Standard Conditioning and As Consolidation Therapy Following Autologous Hematopoietic Stem Cell Transplantation (AutoHCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Primary Analysis of the US Intergroup Double-Blind Randomized Phase III Study Alliance A051301/BMT-CTN 1201

Authors
C Andreadis;O Bobek;E Hsi;T Fenske;S Geyer;P Stiff;B Till;M Horwitz;F Khimani;R Little;S Dinner;J Friedberg;B Kahl;M Perales;S Devine;J Leonard;N Bartlett
Journal / Conference
ASH Annual Meeting (Dec9-12,2023, San Diego, CA), oral
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
CTSU/A051301

Single Cell Transcriptomic Analysis of B-Cell Acute Lymphoblastic Leukemia (B-ALL) Reveals Correlation between Leukemia Cell State, Genetic Alterations and Clinical Outcome

Authors
I Iacobucci;A Zeng;Q Gao;L Garcia Pratt;P Baviskar;S Shah;A Murison;V Voisin;C Bailey;M Lear;A Advani;S Luger;E Paietta;W Stock;J Dick;C Mullighan
Journal / Conference
ASH Annual Meeting (Dec9-12,2023, San Diego, CA), oral
Year
2023
Research Committee(s)
Leukemia

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

Authors
S Luger;X Sun;R Mattison;E Paietta;K Roberts;Y Zhang;J Racevckis;H Lazarus;J Rowe;D Arber;M Wieduwilt;M Liedtke;J Bergeron;B Wood;Y Zhao;G Wu;T Chang;W Zhang;K Pratz;S Dinner;N Frey;S Gore;B Bhatnagar;E Atallah;G Uy;D Jeyakumar;T Lin;C Willman;D DeAngelo;E Sharon;R Little;H Erba;R Stone;C Mullighan;M Litzow;M Tallman
Journal / Conference
ASH Annual Meeting (Dec9-12,2023, San Diego, CA), poster
Year
2023
Research Committee(s)
Leukemia
Study Number(s)
CTSU/E1910

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Authors
A Clark;F Hong;R Finn;A DeMichelle;E Mitchell;J Ziebel;F Arnaldez;F Arnaldez;R Gray;V Wang;L McShane;L Rubinstein;D Patton;P Willams;S Hamilton;M Copur;S Kasbari;R Thind;B Conley;C Arteaga;P O'Dwyer;L Harris;A Chen;K Flaherty
Journal / Conference
Clin Cancer Res 14;29(8):1477-1483
Year
2023
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID36853016
PMC
PMC10102836
Study Number(s)
CTSU/EAY131